Management of acute intermittent porphyria

Bibliography

• Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic and molecular bases of inherited disease. McGraw-Hill, New York; 2001. p. 2991-3062
   Google Scholar
• Puy H, Gouya L, Deybach JC. Porphyrias. Lancet 2010;375:924-37
   PubMed Web of Science ®Google Scholar
• Anderson KE, Singal AK. Variegate Porphyria. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors, GeneReviews^™ [Internet]. University of Washington, Seattle, WA; 1993-2013. 2013
   Google Scholar
• Bissell DM, Wang B, Cimino T, Lai J. Hereditary Coproporphyria. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors, GeneReviews^™ [Internet]. University of Washington, Seattle, WA; 1993-2013. 2012
   Google Scholar
• Sardh E, Harper P, Andersson DE, Floderus Y. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med 2009;20:201-7
   PubMed Web of Science ®Google Scholar
• Stein P, Badminton M, Barth J, et al. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem 2013;50:217-23
   PubMed Web of Science ®Google Scholar
• Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta 2006;1763:723-36
   PubMed Web of Science ®Google Scholar
• Tian Q, Li T, Hou W, et al. Lon peptidase 1 (LONP1)-dependent breakdown of mitochondrial 5-aminolevulinic acid synthase protein by heme in human liver cells. J Biol Chem 2011;286:26424-30
   PubMed Web of Science ®Google Scholar
• Badminton MN, Elder GH. Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 2005;28:277-86
   PubMed Web of Science ®Google Scholar
• Online Mendelian Inheritance in Man Website. Available from: http://omim.org/entry/609806 [Accessed 24 September 2013]
   Google Scholar
• Stenson PD, Ball EV, Howells K, et al. The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalized genomics. Hum Genomics 2009;4:69-72
   PubMedGoogle Scholar
• Nordmann Y, Puy H, Da Silva V, et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med 1997;242:213-17
   PubMed Web of Science ®Google Scholar
• Whatley S, Badminton M. Prevalence of Potentially Pathogenic Mutations in the HMBS Gene in Subjects Enrolled in the 1000 Genome Project. International Congress of Porphyrins and Porphyrias. Lucerne, Switzerland. Clin Chem Lab Med 2013;eA1-eA64( P48). Available from: http://www.porphyrinsandporphyrias.org/
   Google Scholar
• Elder G, Harper P, Badminton M, et al. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis 2013;36:849-57
   PubMed Web of Science ®Google Scholar
• Beukeveld GJJ, Wolthers BG, Nordmann Y, et al. A retrospective study of a patient with homozygous form of acute intermittent porphyria. J Inherit Metab Dis 1990;13:673-83
   PubMed Web of Science ®Google Scholar
• Llewellyn DH, Smyth SJ, Elder GH, et al. Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene. Hum Genet 1992;89:97-8
   PubMed Web of Science ®Google Scholar
• Hessels J, Voortman G, van der Wagen A, et al. Homozygous acute intermittent porphyria in a 7-year-old boy with massive excretions of porphyrins and porphyrin precursors. J Inherit Metab Dis 2004;27:19-27
   PubMed Web of Science ®Google Scholar
• Solis C, Martinez-Bermejo A, Naidich TP, et al. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Arch Neurol 2004;61:1764-70
   PubMedGoogle Scholar
• Andersson C, Floderus Y, Wikberg A, Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study. Scand J Clin Lab Invest 2000;60:643-8
   PubMed Web of Science ®Google Scholar
• Fraunberg MV, Pischik E, Udd L, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 finnish and russian patients with acute intermittent porphyria. Medicine (Baltimore) 2005;84:35-47
   PubMed Web of Science ®Google Scholar
• Bustad HJ, Vorland M, Ronneseth E, et al. Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria. Biosci Rep 2013;33(4), doi:10.1042/BSR20130045
   PubMedGoogle Scholar
• Thunell S. (Far) Outside the box: genomic approach to acute porphyria. Physiol Res 2006;55:S43-66
   PubMed Web of Science ®Google Scholar
• Thunell S, Harper P, Brock A, Petersen NE. Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scand J Clin Lab Invest 2000;60:541-59
   PubMed Web of Science ®Google Scholar
• Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 2002;48:1891-900
   PubMed Web of Science ®Google Scholar
• Floderus Y, Sardh E, Moller C, et al. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Clin Chem 2006;52:701-7
   PubMed Web of Science ®Google Scholar
• Marsden JT, Rees DC. Urinary excretion of porphyrins, porphobilinogen and delta-aminolaevulinic acid following an attack of acute intermittent porphyria. J Clin Pathol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 1991;86:1050-6
   PubMed Web of Science ®Google Scholar
• Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993;153:2004-8
   PubMedGoogle Scholar
• Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005;142:439-50
   PubMed Web of Science ®Google Scholar
• Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine 2005;84:48-60
   PubMed Web of Science ®Google Scholar
• Anderson KE, Lee C, Balwani M, Desnick RJ. The Porphyrias (Chapter 85). Kliegman: Nelson textbook of pediatrics. 19th edition. Saunders, Philadelphia, PA; 2011. p. 517.e1-e17
   Google Scholar
• European Porphyria Initiative Website. Available from: http://www.porphyria-europe.org/ [Accessed 27 October 2013]
   Google Scholar
• Sardh E, Andersson DE, Henrichson A, Harper P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand) 2009;55:66-71
   PubMed Web of Science ®Google Scholar
• Handschin C, Lin J, Rhee J, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 2005;122:505-15
   PubMed Web of Science ®Google Scholar
• Anderson KE, Bonkovsky HL, Bloomer JR, Shedlofsky SI. Reconstitution of hematin for intravenous infusion. Ann Intern Med 2006;144:537-8
   PubMed Web of Science ®Google Scholar
• Tenhunen R, Tokola O, Lindén IB. Haem arginate: a new stable haem compound. J Pharm Pharmacol 1987;39:780-6
   PubMed Web of Science ®Google Scholar
• Mustajoki P. Heme arginate for acute porphyric attacks: experience with Finnish patients. In: New therapeutic approach to hepatic porphyries. Mustajoki P, editor, Leiras Medica Vammalan Kirjapaino Oy, Helsinki Finland; 1986. p. 51-5
   Google Scholar
• Orphan Europe Recordati Group Website. Available from: http://www.orphan-europe.com/ [Accessed 27 October 2013]
   Google Scholar
• Recordati Rare Diseases Website. Available from: http://www.recordatirarediseases.com/ [Accessed 27 October 2013]
   Google Scholar
• Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice implications. Am J Med 2006;119:801.e19-24
   Web of Science ®Google Scholar
• Daimon M, Susa S, Igarashi M, et al. Administration of heme arginate, but not hematin, caused anaphylactic shock. Am J Med 2001;110:240
   PubMed Web of Science ®Google Scholar
• Morris DL, Dudley MD, Pearson RD. Coagulopathy associated with hematin treatment for acute intermittent porphyria. Ann Intern Med 1981;95:700-1
   PubMed Web of Science ®Google Scholar
• Mustajoki P, Tenhunen R, Pierach C, Volin L. Heme in the treatment of porphyrias and hematological disorders. Semin Hematol 1989;26:1-9
   PubMed Web of Science ®Google Scholar
• Dhar GJ, Bossenmaier I, Cardinal R, et al.Watson CJ. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand 1978;203:437-43
   PubMedGoogle Scholar
• Frei P, Minder EI, Corti N, et al. Liver transplantation because of acute liver failure due to heme arginate overdose in a patient with acute intermittent porphyria. Case Rep Gastroenterol 2012;6:190-6
   PubMedGoogle Scholar
• Bissell DM. Treatment of acute hepatic porphyria with hematin. J Hepatol 1988;6:1-7
   PubMed Web of Science ®Google Scholar
• Sardh E, Wahlin S, Bjornstedt M, et al. High risk of primary liver cancer in a cohort of 179 patients with acute HEPATIC Porphyria. J Inherit Metab Dis 2013;36:1063-71
   PubMed Web of Science ®Google Scholar
• Aarsand AK, Petersen PH, Sandberg S. Estimation and Application of Biological Variation of Urinary {delta}-Aminolevulinic Acid and Porphobilinogen in Healthy Individuals and in Patients with Acute Intermittent Porphyria. Clin Chem 2006;52:650-6
   PubMed Web of Science ®Google Scholar
• Andersson C, Innala E, Bäckström T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med 2003;254:176-83
   PubMed Web of Science ®Google Scholar
• Herrick AL, McColl KE, Wallace AM, et al. LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. Q J Med 1990;75:355-63
   PubMedGoogle Scholar
• Innala E, Backstrom T, Bixo M, Andersson C. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand 2010;89:95-100
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Vicente JJ, Vanrell JA. Use of gonadotropin-releasing hormone analog with tibolone to prevent cyclic attacks of acute intermittent porphyria. Metabolism 2001;50:995-6
   PubMed Web of Science ®Google Scholar
• Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992;71:1-13
   PubMed Web of Science ®Google Scholar
• Almazán MCdM, Acuna M, Garrido-Astray C, et al. Porfirias agudas en la unidad de cuidados intensivos. Emergencias 2011;24:454-8
   Google Scholar
• Cable EE, Pepe JA, Donohue SE, et al. Effects of mifepristone (RU-486) on heme metabolism and cytochromes P-450 in cultured chick embryo liver cells. Possible implications for acute porphyria. Eur J Biochem 1994;225:651-7
   PubMedGoogle Scholar
• Aggarwal N, Bagga R, Sawhney H, et al. Pregnancy with acute intermittent porphyria: a case report and review of literature. J Obstet Gynaecol Res 2002;28:160-2
   PubMed Web of Science ®Google Scholar
• Kanaan C, Veille JC, Lakin M. Pregnancy and acute intermittent porphyria. Obstet Gynecol Surv 1989;44:244-9
   PubMedGoogle Scholar
• Marsden JT, Rees DC. A retrospective analysis of outcome of pregnancy in patients with acute porphyria. J Inherit Metab Dis 2010;33:591-6
   PubMed Web of Science ®Google Scholar
• Tollanes MC, Aarsand AK, Sandberg S. Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study. J Inherit Metab Dis 2011;34:217-23
   PubMed Web of Science ®Google Scholar
• Vassiliou D, Harper P, Sardh E. Low risk for complications during pregnancy in women with acute intermittent porphyria (AIP) and biochemical signs of active disease. international congress of porphyrins and porphyrias. lucerne, Switzerland. Clin Chem Lab Med 2013;eA1-eA64( OC32). Available from: http://www.porphyrinsandporphyrias.org/
   Google Scholar
• The Drug Database for Acute Porphyria Website. Available from: http://www.drugs-porphyria.org [Accessed 27 October 2013]
   Google Scholar
• Badminton MN, Deybach JC. Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol 2006;13:668-9
   PubMed Web of Science ®Google Scholar
• Wenger S, Meisinger V, Brucke T, Deecke L. Acute porphyric neuropathy during pregnancy–effect of haematin therapy. Eur Neurol 1998;39:187-8
   PubMed Web of Science ®Google Scholar
• Seiden WB, Kelly LP, Ali R. Acute intermittent porphyria associated with ovarian stimulation. A case report. J Reprod Med 2003;48:201-3
   PubMed Web of Science ®Google Scholar
• Wang JG, Guarnaccia M, Weiss SF, et al. Initial presentation of undiagnosed acute intermittent porphyria as a rare complication of ovulation induction. Fertil Steril 2006;86:462.e1-3
   Web of Science ®Google Scholar
• Hift RJ, Thunell S, Brun A. Drugs in porphyria: from observation to a modern algorithm-based system for the prediction of porphyrogenicity. Pharmacol Ther 2011;132:158-69
   PubMed Web of Science ®Google Scholar
• Thunell S, Pomp E, Brun A. Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol 2007;64:668-79
   PubMed Web of Science ®Google Scholar
• American Porphyria Foundation Website. Available from: http://www.porphyriafoundation.com/ [Accessed 27 October 2013]
   Google Scholar
• Desnick RJ, Balwani M, Anderson KE. Inherited porphyrias (Chapter 99). In: Rimoin DL, Pyeritz RE, Korf B, editors, Emery and rimoin's principles and practice of medical genetics. 6th edition. Elsevier Ltd, Philadelphia, PA; 2013. p. 1-32
   Google Scholar
• Bylesjo I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest 2009;69:612-18
   PubMed Web of Science ®Google Scholar
• Doss MO, Kuhnel A, Gross U. Alcohol and porphyrin metabolism. Alcohol Alcohol 2000;35:109-25
   PubMed Web of Science ®Google Scholar
• Porphyria South Africa Website. Available from: http://web.uct.ac.za/depts/porphyria/ [Accessed 27 October 2013]
   Google Scholar
• Deybach JC, Badminton M, Puy H, et al. European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiol Res 2006;55:S67-73
   PubMed Web of Science ®Google Scholar
• de Rooij FWM, Edixhoven A, Wilson JHP. Porphyria: a diagnostic approach. In: Kadish KM, Smith KM, Guilard R, editors, The porphyrin handbook. Academic Press, USA; 2003. p. 211-45
   Google Scholar
• Deacon AC, Elder GH. ACP Best practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol 2001;54:500-7
   PubMed Web of Science ®Google Scholar
• Elder GH, Smyth SJ. Porphyrins and porphobilinogen. In: Techniques in diagnostic human biochemical genetics. A Laboratory Manual Wiley-Liss, Inc., USA; 1991. p. 327-44
   Google Scholar
• Thunell S. Hydroxymethylbilane Synthase (HMBS) Deficiency. GeneReviews, Published on NCBI Bookshelf. 2010. Available from: www.geneclinics.org
   Google Scholar
• Aarsand AK, Villanger JH, Stole E, et al. European specialist porphyria laboratories: diagnostic strategies, analytical quality, clinical interpretation, and reporting as assessed by an external quality assurance program. Clin Chem 2011;57:1514-23
   PubMed Web of Science ®Google Scholar
• RCPA Quality Assurance Programs Website. Available from: http://www.rcpaqap.com.au/ [Accessed 29 October 2013]
   Google Scholar
• Lee JS, Anvret M. Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria. Proc Natl Acad Sci USA 1991;88:10912-15
   PubMed Web of Science ®Google Scholar
• Floderus Y, Shoolingin-Jordan P, Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 2002;62:288-97
   PubMed Web of Science ®Google Scholar
• Thunell S, Floderus Y, Henrichson A, Harper P. Porphyria in Sweden. Physiol Res 2006;55:S109-18
   PubMed Web of Science ®Google Scholar
• Delaby C, To-Figueras J, Deybach JC, et al. Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of acute intermittent porphyria patients. J Intern Med 2009;266:277-85
   PubMed Web of Science ®Google Scholar
• Miyagi K, Cardinal R, Bossenmaier I, Watson CJ. The serum porphobilinogen nd hepatic porphobilinogen deaminase in normal and porphyric individuals. J Lab Clin Med 1971;78:683-95
   PubMed Web of Science ®Google Scholar
• Shoolingin-Jordan PM, Al-Dbass A, McNeill LA, et al. Human porphobilinogen deaminase mutations in the investigation of the mechanism of dipyrromethane cofactor assembly and tetrapyrrole formation. Biochem Soc Trans 2003;31:731-5
   PubMed Web of Science ®Google Scholar
• Unzu C, Sampedro A, Sardh E, et al. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse. PLoS One 2012;7:e32978
   PubMed Web of Science ®Google Scholar
• Meissner P, Adams P, Kirsch R. Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J Clin Invest 1993;91:1436-44
   PubMed Web of Science ®Google Scholar
• Phillips JD, Bergonia HA, Reilly CA, et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA 2007;104:5079-84
   PubMed Web of Science ®Google Scholar
• Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72
   PubMed Web of Science ®Google Scholar
• Lipschutz DE, Reiter JM. Acute intermittent porphyria with inappropriately elevated ADH secretion. J Am Med Assoc 1974;230:716-17
   PubMed Web of Science ®Google Scholar
• Usalan C, Erdem Y, Altun B, et al. Severe hyponatremia due to SIADH provoked by acute intermittent porphyria. Clin Nephrol 1996;45:418
   PubMed Web of Science ®Google Scholar
• Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003;17:471-503
   PubMed Web of Science ®Google Scholar
• Devars du Mayne JF, Deybach JC, et al. [Rhabdomyolysis in acute intermittent porphyria] (letter) Rhabdomyolyse au cours d'une porphyrie aiguë intermittente. Presse Méd 1987;16:310
   PubMedGoogle Scholar
• Garcia-Martul M, Santana-Cabrera L, Santos-Moyano Z, Sanchez-Palacios M. [Rhabdomyolysis after correction of severe hyponatremia due to an attack of acute intermittent porphyria]. Nefrologia 2008;28:563-4
   PubMed Web of Science ®Google Scholar
• Marsden JT, Peters TJ. Rhabdomyolysis in a patient with acute intermittent porphyria. Ann Clin Biochem 2004;41:341-3
   PubMed Web of Science ®Google Scholar
• Yrjonen A, Pischik E, Mehtala S, Kauppinen R. A novel 19-bp deletion of exon 15 in the HMBS gene causing acute intermittent porphyria associating with rhabdomyolysis during an acute attack. Clin Genet 2008;74:396-8
   PubMed Web of Science ®Google Scholar
• D'Amico A, Bertini E. Metabolic neuropathies and myopathies. Handb Clin Neurol 2013;113:1437-55
   PubMedGoogle Scholar
• Celik M, Forta H, Dalkilic T, Babacan G. MRI reveals reversible lesions resembling posterior reversible encephalopathy in porphyria. Neuroradiology 2002;44:839-41
   PubMed Web of Science ®Google Scholar
• Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-grand) 2009;55:72-83
   PubMed Web of Science ®Google Scholar
• Stevens CJ, Heran MK. The many faces of posterior reversible encephalopathy syndrome. Br J Radiol 2012;85:1566-75
   PubMed Web of Science ®Google Scholar
• Yen PS, Chen CJ, Lui CC, et al. Diffusion-weighted magnetic resonance imaging of porphyric encephalopathy: a case report. Eur Neurol 2002;48:119-21
   PubMed Web of Science ®Google Scholar
• Maramattom BV, Zaldivar RA, Glynn SM, et al. Acute intermittent porphyria presenting as a diffuse encephalopathy. Ann Neurol 2005;57:581-4
   PubMed Web of Science ®Google Scholar
• Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: what's certain, what's new? Pract Neurol 2011;11:136-44
   PubMedGoogle Scholar
• Kuo HC, Huang CC, Chu CC, et al. Neurological complications of acute intermittent porphyria. Eur Neurol 2011;66:247-52
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Quint DJ, Lynch JP. MR imaging of porphyric encephalopathy. AJR Am J Roentgenol 1994;162:1218-20
   PubMed Web of Science ®Google Scholar
• Bicknell SG, Stewart JD. Neuroimaging findings in acute intermittent porphyria. Can J Neurol Sci 2011;38:656-8
   PubMed Web of Science ®Google Scholar
• Black KS, Mirsky P, Kalina P, et al. Angiographic demonstration of reversible cerebral vasospasm in porphyric encephalopathy. AJNR Am J Neuroradiol 1995;16:1650-2
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Siao P, Roig Z, et al. Case records of the Massachusetts General Hospital. Case 20-2008. A 57-year-old woman with abdominal pain and weakness after gastric bypass surgery. N Engl J Med 2008;358:2813-25
   PubMedGoogle Scholar
• King PH, Bragdon AC. MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria. Neurology 1991;41:1300-2
   PubMed Web of Science ®Google Scholar
• Shen FC, Hsieh CH, Huang CR, et al. Acute intermittent porphyria presenting as acute pancreatitis and posterior reversible encephalopathy syndrome. Acta Neurol Taiwan 2008;17:177-83
   PubMedGoogle Scholar
• Utz N, Kinkel B, Hedde JP, Bewermeyer H. MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology 2001;43:1059-62
   PubMed Web of Science ®Google Scholar
• Kupferschmidt H, Bont A, Schnorf H, et al. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med 1995;123:598-600
   PubMed Web of Science ®Google Scholar
• Carvalho AA, Arcari DD. Acute intermittent porphyria after gastroplasty. Arq Neuropsiquiatr 2011;69:992
   PubMed Web of Science ®Google Scholar
• Danion F, Guillot M, Castelain V, et al. An uncommon option for surviving bariatric surgery: regaining weight!. Am J Med 2012;125:e1-2
   PubMed Web of Science ®Google Scholar
• Andant C, Puy H, Bogard C, et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000;32:933-9
   PubMed Web of Science ®Google Scholar
• Innala E, Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med 2011;269:538-45
   PubMed Web of Science ®Google Scholar
• Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 1988;57:117-20
   PubMed Web of Science ®Google Scholar
• Lithner F, Wetterberg L. Hepatocelluar carcinoma in patients with acute intermittent porphyria. Acta Med Scand 1984;215:271-4
   PubMedGoogle Scholar
• Schneider-Yin X, van Tuyll van Serooskerken AM, Went P, et al. Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol 2010;90:512-15
   PubMed Web of Science ®Google Scholar
• Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol 2012;65:976-80
   PubMed Web of Science ®Google Scholar
• Deybach JC, Puy H. Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa. J Intern Med 2011;269:521-4
   PubMed Web of Science ®Google Scholar
• Groeschl RT, Pilgrim CH, Hanna EM, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Yazici C, Niemeyer DJ, Iannitti DA, Russo MW. Hepatocellular carcinoma and cholangiocarcinoma: an update. Expert Rev Gastroenterol Hepatol 2014;8(1):63-82
   PubMed Web of Science ®Google Scholar
• Korem M, Ackerman Z, Sciaki-Tamir Y, et al. Postpartum acute kidney failure and hyponatremia: a clinical enigma. Isr Med Assoc J 2004;6:639-41
   PubMed Web of Science ®Google Scholar
• Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med 2000;248:319-25
   PubMed Web of Science ®Google Scholar
• Marsden JT, Chowdhury P, Wang J, et al. Acute intermittent porphyria and chronic renal failure. Clin Nephrol 2008;69:339-46
   PubMed Web of Science ®Google Scholar
• Onozato ML, Tojo A, Kamijo A, et al. Tubulointerstitial nephritis associated with acute intermittent porphyria. Clin Nephrol 2001;55:171-4
   PubMed Web of Science ®Google Scholar
• Asselbergs FW, Kremer Hovinga TK, Bouwsma C, van Ingen J. Acute intermittent porphyria as a cause of respiratory failure: case report. Am J Crit Care 2009;18:180-78
   PubMed Web of Science ®Google Scholar
• Wahlin S, Harper P, Sardh E, et al. Combined liver and kidney transplantation in acute intermittent porphyria. Transpl Int 2010;23:e18-21
   PubMed Web of Science ®Google Scholar
• Annigeri RA, Ganesan VM. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) and neurological crisis due to acute intermittent porphyria, successfully treated with haemodialysis. J Assoc Physicians India 2007;55:667-9
   PubMedGoogle Scholar
• Prabahar MR, Manorajan R, Sathiyakumar D, et al. Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries. Hemodial Int 2008;12:34-8
   PubMed Web of Science ®Google Scholar
• Sita D, Maurri S, Groppi C, et al. Possible effectiveness of plasmapheresis on the neurological complications in a case of acute intermittent porphyria. Ital J Neurol Sci 1984;5:299-302
   PubMedGoogle Scholar
• Laiwah ACY, Junor B, Macphee GJA, et al. Charcoal haemoperfusion and haemodialysis in acute intermittent porphyria. BMJ 1983;287:1746-7
   PubMedGoogle Scholar
• Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004;363:705-6
   PubMed Web of Science ®Google Scholar
• Stojeba N, Meyer C, Jeanpierre C, et al. Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 2004;10:935-8
   PubMed Web of Science ®Google Scholar
• Seth AK, Badminton MN, Mirza D, et al. Liver transplantation for porphyria: who, when, and how? Liver Transpl 2007;13:1219-27
   PubMed Web of Science ®Google Scholar
• Wahlin S, Harper P. Liver transplantation in acute hepatic porphyria and erythropoietic protoporphyria. In: Ferreira G, editor, Handbook of porphyrin science. World Scientific Publishers, USA; 2013
   Google Scholar
• Dowman JK, Gunson BK, Mirza DF, et al. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl 2012;18:195-200
   PubMed Web of Science ®Google Scholar
• Barone GW, Gurley BJ, Anderson KE, et al. The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. J Clin Pharmacol 2001;41:113-15
   PubMed Web of Science ®Google Scholar
• Nunez DJ, Williams PF, Herrick AL, et al. Renal transplantation for chronic renal failure in acute porphyria. Nephrol Dial Transplant 1987;2:271-4
   PubMedGoogle Scholar
• Turton-Weeks S, Barone GW, Gurley BJ, et al. Pretransplant evaluation of a patient with acute intermittent porphyria. Prog Transplant 2001;11:214-16
   PubMedGoogle Scholar
• Warholm C, Wilczek H. Renal transplantation in a case of acute intermittent porphyria. J Clin Pharmacol 2003;43:1158-60
   PubMed Web of Science ®Google Scholar
• Yin Z, Wahlin S, Ellis EC, et al. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Cell Transplant 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Puppi J, Modo M, Dhawan A, et al. Ex vivo magnetic resonance imaging of transplanted hepatocytes in a rat model of acute liver failure. Cell Transplant 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Johansson A, Nowak G, Möller C, et al. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria. Mol Ther 2004;10:337-43
   PubMed Web of Science ®Google Scholar
• Unzu C, Sampedro A, Mauleon I, et al. Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol Ther 2011;19:243-50
   PubMed Web of Science ®Google Scholar
• Unzu C, Sampedro A, Mauleon I, et al. Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice. Hum Mol Genet 2013;22:2929-40
   PubMed Web of Science ®Google Scholar
• Paneda MA, Lopez-Franco E, Kaeppel C, et al. Safety and liver transduction efficacy of rAAV5-cohPBGD in non-human primates: A potential therapy for acute intermitent porphyria. Hum Gene Ther 2013;24(12):1007-17
   PubMed Web of Science ®Google Scholar
• Prieto J. Gene therapy in the acute porphyrias. International Congress of Porphyrins and Porphyrias. Lucerne, Switzerland. Clin Chem Lab Med 2013;eA1-eA64( Oral). Available from: http://www.porphyrinsandporphyrias.org/
   Web of Science ®Google Scholar
• AIPGENE Website. Available from: http://www.aipgene.org/ [Accessed 27 October 2013]
   Google Scholar
• Alnylam Pharmaceuticals Website. Available from: http://www.alnylam.com/ [Accessed 27 October 2013]
   Google Scholar
• Querbes W, Liebow A, Yasuda M, et al. siRNA Targeting of Aminolevulinic Acid Synthase (ALAS1) for the Treatment of Acute Intermittent Porphyria International Congress of Porphyrins and Porphyrias. Lucerne Switzerland. Clin Chem Lab Med 2013;eA1-eA64( OC21). Available from: http://www.porphyrinsandporphyrias.org/
   Google Scholar
• Bustad HJ, Toska K, Sandberg S, et al. Searching for Pharmacological Chaperones Aiding to Stabilize Hydroxymethylbilane Synthase. International Congress of Porphyrins and Porphyrias. Lucerne, Switzerland. Clin Chem Lab Med 2013;eA1-eA64( OC19). Available from: http://www.porphyrinsandporphyrias.org/
   Google Scholar
• Jeans JB, Savik K, Gross CR, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 1996;65:269-73
   PubMed Web of Science ®Google Scholar
• Aarsand AK, Baravelli C, Elder G, et al. The development of the European porphyria registry (EPR). International congress of porphyrins and porphyrias. Lucerne, Switzerland. Clin Chem Lab Med 2013;eA1-eA64( P53). Available from: http://www.porphyrinsandporphyrias.org/
   Web of Science ®Google Scholar
• RareConnect Website. Available from: https://www.rareconnect.org/en/community/porphyria [Accessed 27 October 2013]
   Google Scholar
• Schneider A, Attaran M, Meier PN, et al. Hepatocyte transplantation in an acute liver failure due to mushroom poisoning. Transplantation 2006;82:1115-16
   PubMed Web of Science ®Google Scholar
• Waelzlein JH, Puppi J, Dhawan A. Hepatocyte transplantation for correction of inborn errors of metabolism. Curr Opin Nephrol Hypertens 2009;18:481-8
   PubMed Web of Science ®Google Scholar
• High KA, Aubourg P. rAAV human trial experience. Methods Mol Biol 2011;807:429-57
   PubMedGoogle Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-65
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819-29
   PubMed Web of Science ®Google Scholar
• Yeung Laiwah AC, Moore MR, Goldberg A. Pathogenesis of acute porphyria. Q J Med 1987;63:377-92
   PubMedGoogle Scholar
• Lin CS, Lee MJ, Park SB, Kiernan MC. Purple pigments: the pathophysiology of acute porphyric neuropathy. Clin Neurophysiol 2011;122:2336-44
   PubMed Web of Science ®Google Scholar
• Ferrer MD, Sureda A, Tauler P, et al. Impaired lymphocyte mitochondrial antioxidant defences in variegate porphyria are accompanied by more inducible reactive oxygen species production and DNA damage. Br J Haematol 2010;149:759-67
   PubMed Web of Science ®Google Scholar
• Dowman JK, Gunson BK, Bramhall S, et al. Liver transplantation from donors with acute intermittent porphyria. Ann Intern Med 2011;154:571-2
   PubMed Web of Science ®Google Scholar
• Gorchein A, Webber R. Delta-aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin Sci (Lond) 1987;72:103-12
   PubMed Web of Science ®Google Scholar
• Mustajoki P, Timonen K, Gorchein A, et al. Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Invest 1992;22:407-11
   PubMed Web of Science ®Google Scholar
• Hu Y, Shen H, Keep RF, Smith DE. Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem 2007;103:2058-65
   PubMed Web of Science ®Google Scholar
• Sylantiev C, Schoenfeld N, Mamet R, et al. Acute neuropathy mimicking porphyria induced by aminolevulinic acid during photodynamic therapy. Muscle Nerve 2005;31:390-3
   PubMed Web of Science ®Google Scholar